UK's MHRA Says Capivasertib Approved To Treat Patients With Advanced Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Capivasertib for the treatment of patients with advanced breast cancer.
July 17, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca (AZN) has received approval from the UK's MHRA for its drug Capivasertib to treat advanced breast cancer. This regulatory approval could boost the company's stock in the short term.
The approval of Capivasertib by the MHRA is a significant milestone for AstraZeneca, likely leading to increased sales and revenue. This positive regulatory news is expected to have a favorable impact on AZN's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100